Thus the inhibition of the intestinal DGAT1 may be sufficient to improve metabolic disorders, suggesting that the intestine-targeted DGAT1 inhibitor shows beneficial metabolic effects without skin aberrations. This evidence concerns the gene DGAT1 and neoplasm.